Tomás Pascual Martínez, Head Breast and Gynecologic Cancer Section, Medical Oncology Deparment at Hospital Clínic de Barcelona, shared on LinkedIn:
“The SABCS 2026 program is out, and I am honored to present two poster spotlights on behalf of SOLTI cancer research and our collaborators.
- PS3-5: Poster Spotlight 3: HER2DX ERBB2 mRNA Expression Predicts Clinical Benefit from Trastuzumab Deruxtecan in Advanced Breast Cancer: The HER2-PREDICT (SOLTI-1804) Study
- PS10-4: Poster Spotlight 10: Ribociclib versus palbociclib in HER2-enriched HR+/HER2− metastatic breast cancer: results from the randomized HARMONIA (SOLTI-2101/AFT-58) phase III trial
Looking forward to the discussion in San Antonio!”
This also can be interesting:
HER2DX in Early HER2-Positive Breast Cancer: Toward Biology-Guided Treatment Intensity
